Pralatrexate

Drug Profile

Pralatrexate

Alternative Names: 10-Propargyl-10-deazaaminopterin; Difolta; Folotyn; PDX; Pralatrexate injection

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center; Southern Research Institute; SRI International
  • Developer Allos Therapeutics; Mundipharma International; Rafa Laboratories
  • Class Antineoplastics; Pterins; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - T cell lymphoma; Follicular lymphoma; Peripheral T-cell lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Bladder cancer; Cutaneous T cell lymphoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • No development reported B cell lymphoma; Bladder cancer; Breast cancer; Cutaneous T cell lymphoma; Hodgkin's disease; Mesothelioma; Non-Hodgkin's lymphoma; Non-small cell lung cancer

Most Recent Events

  • 11 Jan 2016 Servier in-licenses pralatrexate (Folotyn®) from Spectrum Pharmaceuticals in Canada
  • 31 Oct 2015 Phase-I clinical trials in Peripheral T-cell lymphoma (Newly diagnosed, Combination therapy) in USA (IV)
  • 01 Oct 2015 Spectrum Pharmaceuticals plans a phase I trial (Combination therapy, Newly diagnosed) for Peripheral T-cell lymphoma in USA (NCT02594267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top